Press Release

Prenetics Announces Fourth Quarter and Full Year 2022 Financial Results, New Business Strategy Focused on Precision Oncology
Mar 14, 2023 22:05 JST

Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading genomics and precision oncology company, today announced financial results for the fourth quarter and full year ended December 31, 2022.

More info..

Prenetics Announces Formation of Scientific Advisory Board to Support New Business Strategy in Precision Oncology
Mar 04, 2023 15:40 JST

Prenetics Global Limited (NASDAQ: PRE), a leader in genomic and diagnostic testing, is proud to announce the formation of a new Prenetics Scientific Advisory Board (the 'SAB') to provide strategic input based on their scientific knowledge and clinical expertise to help guide the further development of Prenetics' diagnostic cancer genomics platform.
More info..

Cantor Fitzgerald Initiates Coverage on Prenetics with "Overweight" Rating Jan 26, 2023 12:16 JST It is reported that Cantor Fitzgerald initiated coverage on Prenetics Global (PRE.US) with "Overweight" rating and target price at USD7.00. More info..

Prenetics Owned ACT Genomics Receives FDA Clearance for ACTOnco, the First Asia-Based Company to Receive Clearance for a Comprehensive Genomic Profiling Test for All Solid Tumors
Jan 11, 2023 11:19 JST

Prenetics Global Limited (NASDAQ: PRE) a leader in genomic and diagnostic testing, today announced that ACT Genomics, a company which Prenetics recently acquired a majority stake in, has received clearance from the U.S. Food and Drug Administration (FDA) for ACTOnco
More info..

Prenetics Acquires ACT Genomics; First M&A Deal since IPO, Set to Expand Footprint in Cancer Genomics
Dec 16, 2022 19:57 JST

Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a global leader in genomic and diagnostic testing, is acquiring a majority stake of ACT, an Asia based genomics company specializing in precision oncology with operations in Hong Kong, Taiwan, Japan, Singapore, Thailand and the UK, for an upfront consideration consisting of 19.9 million shares of Prenetics common stock and US $20 million cash (the "transaction").
More info..

Prenetics Announces US$20 Million Stock Repurchase Program and Inclusion into the MSCI Global Micro Cap Index
Nov 30, 2022 22:43 JST

Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a global leader in genomic and diagnostic testing, today announced that its board of directors has authorized a share repurchase program, and that it has been included as a constituent stock in the MSCI Global Micro Cap Index (Hong Kong), with such inclusion to become effective after the U.S. market close today.
More info..

Prenetics Announces Record Third Quarter 2022 Financial Results and Raises Full Year 2022 Revenue and EBITDA Guidance Nov 10, 2022 21:36 JST Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a global leader in genomic and diagnostic testing, today announced its unaudited financial results for the third quarter ended September 30, 2022. More info..

Prenetics Announces Second Quarter 2022 Financial Results and Raises Full Year Adjusted EBITDA Outlook Sep 09, 2022 21:54 JST Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a global leader in genomic and diagnostic testing, today announced its unaudited financial results for the second quarter ended June 30, 2022. More info..